Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study
Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study
复制标题
DOI：
10.1210/jc.83.12.4257
复制
发表时间：
1998-12-01
影响因子：
5.8
通讯作者：
Kiel, DP
中科院分区：
文献类型：
--
作者：
Langlois, JA;Rosen, CJ;Kiel, DP
很少有关于GH轴和骨骼的研究专门针对老年人。本研究的目的是确定胰岛素样生长因子I（IGF-I）和骨矿物质密度（BMD）之间的关联，年龄在72-94岁的425名女性和257名男性参与了1992-1993年心脏研究中的心脏骨质疏松研究部分。采用放射免疫法测定血清IGF-I水平。在三个股骨部位和腰椎的骨密度测定双X线吸收法，并在半径的单光子吸收法。IGF-I水平与女性所有五个部位（沃德区，股骨颈，转子，桡骨和腰椎）的BMD呈正相关，调整了体重减轻和其他因素（P小于或等于0.01）和蛋白质摄入量（0.006 < P < 0.07）。与IGF-I水平最低的四个五分位数相比，IGF-I水平最高的五分位数（大于或等于179 g/L）的女性在股骨和脊柱的三个部位都有明显的高BMD阈值效应（P < 0.03），但在桡骨没有。IGF-I与男性BMD无显著相关性。这些结果表明，较高的IGF-I水平与老年妇女的BMD较高，并建议未来的临床试验采用生长激素可能有一个作用，在治疗老年妇女骨质疏松症的发展。
Few studies of the GH axis and bone have focused specifically on elderly people. The objective of this study was to determine the association between insulin-like growth factor I (IGF-I) and bone mineral density (BMD) in 425 women and 257 men aged 72-94 who participated in the Framingham Osteoporosis Study component of the Framingham Heart Study in 1992-1993. Serum IGF-I level was determined by RIA. BMD at three femoral sites and the lumbar spine was determined by dual x-ray absorptiometry, and at the radius by single-photon absorptiometry. IGF-I level was positively associated with BMD at all five sites (Ward's area, femoral neck, trochanter, radius, and lumbar spine) in women after adjustment for weight loss and other factors (P less than or equal to 0.01) and protein intake in a subset of participants (0.006 < P < 0.07). A threshold effect of higher BMD was evident at each of the 3 femoral sites and the spine (P < 0.03) but not at the radius for women in the highest quintile of IGF-I (greater than or equal to 179 g/liter) vs, those in the lowest four quintiles. IGF-I was not significantly associated with BMD in men. These results indicate that higher IGF-I levels are associated with greater BMD in very old women, and suggest that future clinical trials employing GH may have a role in the development of treatments for older women with osteoporosis.